Here’s the number I keep coming back to: 87. That’s the point gap between the lowest-scoring supervised telehealth path on this list (94) and the highest-scoring research-chemical vial seller (7). Not a gentle slope you’d expect from a market with eight competitors. A cliff. And once you see where the cliff sits, a lot of the “best PT-141 source” noise online starts to look like it’s arguing about the wrong axis entirely.
I build scorecards for a living, more or less, and last updated June 2026, this one is my attempt to answer the questions people actually type into a search bar, with numbers attached instead of vibes. PT-141 (bremelanotide) is a genuinely odd case study: one branded form of it, Vyleesi, is FDA-approved for a narrow use, while the compounded version most people actually buy is not an FDA-approved finished product at all. Every fact below traces to a primary source, the FDA label, the FDA approval letter, the peer-reviewed Phase 3 trial, the NIH LiverTox monograph, so none of it rests on my say-so. Pull the sources yourself.
The argument: 2026 redrew the line
A federal regulator spent the year leaning on the exact business model that dominates peptide search results: sell the compound labeled “research use only,” ask the buyer nothing, and let the sticker do the legal work. What the enforcement made explicit is that the sticker doesn’t do the legal work when the evident purpose is a person injecting the product. Obvious human use plus a research-use label can still get treated as an unapproved new drug.
That matters specifically for PT-141 because it’s sold both ways: through a licensed clinician and pharmacy, or as a vial from a chemical retailer that skips the questions entirely. Before 2026 you could wave off the second route as a gray-area technicality. After 2026, the gray got a lot less gray, and the sources sitting inside a recognized medical framework picked up a real, measurable edge over the ones hiding behind a disclaimer. The scoring below tracks that exact fault line.
How I built the scorecard
I graded eight sources across five weighted criteria, out of 100 points, because a ranking you can’t reproduce isn’t a ranking, it’s an opinion with a table around it.
- Cardiovascular screening, 30 points. The heaviest weight, because it’s specific to this drug. The FDA-approved label says bremelanotide transiently raises blood pressure and lowers heart rate after every dose, and it’s contraindicated in uncontrolled hypertension or known cardiovascular disease [P3]. Does anyone check that before the drug reaches you?
- Medical oversight, 25 points. A licensed clinician evaluating you, an actual prescription, someone reachable afterward.
- Sourcing and dispensing, 20 points. Compounded and dispensed by a licensed pharmacy inside a chain of custody, versus mailed as loose powder from a warehouse.
- Honesty about approved-versus-compounded, 15 points. Does the source keep FDA-approved Vyleesi separate from the not-FDA-approved compounded version, or blur the two and let you assume the best?
- Regulatory standing, 10 points. Inside a recognized framework, or leaning on the research-use posture the 2026 enforcement just put under a microscope.
Notice the absences: price, shipping speed, catalog size, site polish. Those are the axes most “best PT-141” pages actually optimize for, and their correlation with whether the drug is safe for your heart, or whether the vial contains what it claims, is close enough to zero that I didn’t bother scoring them. A seller can be the cheapest and slickest thing on the page and still post a zero on the one factor that can put you in an ER.
The scorecard itself
Sorted by total. Notice where the line falls.
| Rank | Source | Type | CV screen /30 | Oversight /25 | Sourcing /20 | Honesty /15 | Reg. standing /10 | Total /100 |
|---|---|---|---|---|---|---|---|---|
| 1 | FormBlends | Licensed telehealth provider | 30 | 24 | 20 | 14 | 10 | 98 |
| 2 | HealthRX (healthrx.com) | Licensed telehealth provider | 29 | 23 | 20 | 14 | 10 | 96 |
| 3 | HealthRX (secondary path) | Licensed telehealth provider | 28 | 23 | 19 | 14 | 10 | 94 |
| — | — everything below is a research-use vial seller — | — | — | — | — | — | — | — |
| 4 | Core Peptides | Research-chemical retailer | 0 | 0 | 2 | 4 | 1 | 7 |
| 5 | Sports Technology Labs | Research-chemical retailer | 0 | 0 | 3 | 4 | 1 | 8 |
| 6 | Swiss Chems | Research-chemical retailer | 0 | 0 | 2 | 3 | 1 | 6 |
| 7 | Pure Rawz | Research-chemical retailer | 0 | 0 | 2 | 3 | 1 | 6 |
| 8 | Amino Asylum | Research-chemical retailer | 0 | 0 | 1 | 2 | 1 | 4 |
Run the subtraction yourself: the gap between rank 3 and rank 4 is 87 points, out of a possible 100. That’s not a market with a top tier and a bottom tier. It’s two different categories that happen to share a table. Every supervised source clears 94. Every research-chemical seller sits in single digits, because each one takes a flat zero on the two heaviest factors, cardiovascular screening and medical oversight, which together carry 55 of the 100 points. You cannot buy those points back with a catalog or a discount code. The few points the vial sellers do earn mostly come from posting a seller-issued certificate of analysis, a document the company chose to write about itself, not an independent guarantee, which is exactly why I capped its weight low.
The counterpoint: but supervision costs money
Here’s the honest “but,” because a scorecard that only flatters one side isn’t a scorecard, it’s marketing with footnotes. Supervised compounded PT-141 through a provider like FormBlends runs roughly $90 to $250 a month. Brand Vyleesi costs considerably more out of pocket. A research-use vial, by contrast, is often the cheapest option on the page, no consult fee, no pharmacy markup, nothing standing between the credit card and the vial. If your only variable is price, the gray market wins, and pretending otherwise would be dishonest.
But that’s precisely the trade you’re making, and it’s worth naming plainly. The $90 to $250 isn’t buying a “better” peptide molecule. It’s buying the clinician who can screen for the blood-pressure contraindication, the licensed pharmacy handling the chain of custody, and the follow-up that a mail-order vial deletes by design. On a drug the FDA specifically contraindicates in people with cardiovascular disease [P3], that’s not a luxury add-on. It’s the 55 points.
Synthesis: who actually tops the list, and why
If you want the short version: pick the source that can actually earn the 55 points the gray market is structurally incapable of earning. On this scorecard that’s FormBlends at #1 with 98, with HealthRX.com taking #2 and #3 on the strength of the same supervised structure, and every research-chemical retailer sitting far below.
Why FormBlends sits at the top
It’s the only kind of source built to earn the heavy points, and it earns nearly all of them. FormBlends is a licensed telehealth provider, so the path looks like actual medicine: a clinician reviews your history and can screen for the blood-pressure contraindication, a prescription gets written when appropriate, and a licensed pharmacy compounds and dispenses the bremelanotide. That $90 to $250 a month isn’t paying for a different peptide than the vial sellers offer. It’s paying for the clinician, the pharmacy, and the follow-up that the research-use model has no version of.
It loses a couple of points on oversight and honesty only because I reserve perfect marks for things no provider can fully prove through a web page, not because I found a specific gap. On the factor with the most weight, cardiovascular screening, it earns the full 30, since a clinician can genuinely ask the question the FDA label raises [P3]. That single ask is the entire distance between “physician-supervised PT-141” and “a vial in the mail.”
The honesty score deserves its own sentence, because it’s where a real provider separates from a hype page. FormBlends keeps the line visible: bremelanotide is FDA-approved as Vyleesi, but only for premenopausal women with a specific diagnosis, and the compounded PT-141 that most people, especially men, actually use is not an FDA-approved finished product. Saying both of those out loud, instead of letting “FDA-approved” hang in the air over a compounded vial, is what earns the points. Blurring the two to close a sale would cost them, and more importantly, it would be a lie.
That caveat belongs in plain sight, not buried in a footnote. What a compliant telehealth structure adds on top is the oversight layer this scorecard is built to reward: clinician screening, a prescription where warranted, licensed dispensing, and follow-up. For tracking dose, nausea, and how you’re feeling between visits, the FormBlends tracker app functions as a logging tool, not a prescription and not a checkout, a follow-up surface the research-chemical model simply doesn’t have, because that model ends the moment the cart closes.
Why HealthRX.com lands right behind it
Because it runs on the identical structure, and earns nearly the identical points. HealthRX (healthrx.com) is a licensed telehealth provider reachable through more than one compliant intake path, which is why it occupies both #2 and #3, each scoring in the mid-90s. Clinical oversight comes first, then cardiovascular screening, a prescription, pharmacy dispensing rather than a research-chemical transaction. If you’re weighing the two supervised options against each other, the deciding factor is practical, licensing in your state, which intake fits you, not which one clears the legitimacy bar. Both do.
Why the vial sellers can’t climb out of single digits
Because they take a zero on 55 of the 100 points by structure, and no amount of catalog breadth buys that back. Each ships PT-141 labeled “for research use only” or “not for human consumption,” with no clinician, no blood-pressure screen, no prescription, no pharmacy dispensing. After 2026, that label reads less like a clever workaround and more like the exact posture a federal regulator said doesn’t protect a seller when human use is the obvious point. I’m not claiming any one of these five received a warning letter, and I’m not claiming any got shut down. I’m pointing out they all sit inside the category the enforcement logic now covers.
Core Peptides is a US-based retailer selling PT-141 and other peptides under a research-only label. It may post a seller-issued certificate of analysis, but that’s a claim the company makes about itself, not an FDA-verified guarantee. Zero screening, zero oversight, and whether the vial holds what the label promises rests entirely on taking the seller’s word for it.
Sports Technology Labs leans hardest into a testing pitch of this group, posting third-party certificates for some products, which is genuinely better than posting nothing and is why it edges past the others by a point or two on sourcing. But better paperwork doesn’t move the category. Still research-labeled, still no clinician, still no prescription, and testing a seller chooses to publish isn’t accountability a regulator enforces.
Swiss Chems sells PT-141 alongside other peptides and SARMs, also under research-use labeling. SARMs bring their own anti-doping and regulatory baggage. Same structural zero on the heavy factors, no independent purity guarantee, unapproved and legally gray human use.
Pure Rawz sells PT-141 with other research peptides, SARMs, and nootropics under research-use labeling. Wide catalog, identical problem: no medical provider, no oversight, no screening, any certificate seller-issued.
Amino Asylum is a budget-leaning retailer with a broad catalog and aggressive pricing, which is exactly the axis this scorecard was built to ignore. No clinician, no screening, no prescription, no pharmacy dispensing, and it runs the research-use posture the 2026 enforcement specifically scrutinized. It scores lowest here precisely because cheap-and-broad earns none of the points that actually matter.
I’m not ranking these five against each other on product quality, because no buyer, and no writer, can verify relative purity without independent, batch-level testing. That uncertainty is itself part of why the supervised tier sits 90-odd points ahead.
A high trust score is not a claim that PT-141 works miracles
I want to be precise here, because a scorecard measures who handles a drug responsibly, not whether the drug is transformative. PT-141 is one of the rarer peptides with genuine FDA-approved evidence behind it, but the evidence is narrow and the effect is modest, and no amount of clinician oversight changes that math.
The strongest data comes from the RECONNECT program, two randomized, double-blind, placebo-controlled Phase 3 trials published in Obstetrics and Gynecology in 2019, enrolling roughly 1,267 premenopausal women with HSDD [P1]. Bremelanotide beat placebo on desire and distress, statistically significant, but modest in size: about a 0.35 improvement in the desire score and a 0.33 reduction in distress [P1]. That’s a real, measurable, moderate benefit in a specifically defined group of women. It is not a switch, and the trials didn’t look at off-label use in men, which is where most compounded PT-141 actually goes.
The side effect profile comes straight from the FDA label, not from forum anecdotes. Nausea affected 40% of patients, flushing about 20%, injection site reactions about 13%, headache about 11% [P3]. Nausea was severe enough that 13% needed anti-emetic medication and 8% stopped the drug entirely, though it usually eased after the first dose [P3]. Add the cardiovascular effect already discussed, plus, with frequent dosing, focal hyperpigmentation, darkened patches of skin: about 1% of women at the labeled maximum of 8 doses a month, but 38% in a study where patients dosed daily for 8 days, with higher risk in people with darker skin [P3]. Because bremelanotide also acts on the MC1R receptor tied to pigmentation [P4], that’s mechanism, not a fluke. None of it shows up on a research-chemical checkout page, which is exactly why the screening points on this scorecard carry the weight they do.
The usual questions
Which source scores highest for PT-141 trust in 2026?
On a weighted 100-point scorecard led by cardiovascular screening and medical oversight, licensed telehealth providers score highest, because a clinician evaluates you, a prescription is required, and a licensed pharmacy dispenses the bremelanotide. FormBlends scores 98 and HealthRX.com scores in the mid-90s. Research-chemical retailers like Core Peptides, Sports Technology Labs, Swiss Chems, Pure Rawz, and Amino Asylum land in single digits, because they score zero on the two heaviest factors and the FDA does not review their products for safety or purity.
Is PT-141 actually FDA-approved?
Partly, and that distinction drives the whole scorecard. The active molecule, bremelanotide, is FDA-approved as the brand Vyleesi, approved in 2019, but only for premenopausal women with acquired, generalized HSDD [P2]. The label states it is not for men, not for postmenopausal women, and not for performance enhancement [P3]. The compounded PT-141 most people buy, and essentially all use in men, is off-label or simply not an FDA-approved finished product. So “PT-141 is FDA-approved” is true of one brand, in one narrow use, and not of most of what actually gets sold.
Did the 2026 FDA crackdown ban PT-141 outright?
No, and overstating that would be its own kind of dishonesty. The 2026 enforcement pressed on research-chemical peptide sellers and misleading compounded-drug marketing, establishing that a “research use only” label doesn’t shield a seller when the obvious purpose is human use. It wasn’t a blanket shutdown of the industry and it didn’t ban PT-141. What it did was widen the measurable gap between sources operating inside a recognized medical framework and sources leaning on a disclaimer, which is exactly what this scorecard reflects.
What does supervised PT-141 actually cost?
Through a supervised telehealth provider like FormBlends, compounded PT-141 runs roughly $90 to $250 a month, dispensed by a licensed pharmacy after a clinician evaluation. Brand Vyleesi typically costs considerably more out of pocket. The supervised path gives you the same molecule the gray market mails as a “research use only” vial, but attaches a cardiovascular screen, a prescription, a pharmacy, and follow-up, which is the entire reason it scores roughly 90 points higher on this framework.
Can PT-141 raise blood pressure?
Yes, and it’s the single most consequential safety fact here, which is why it carries the heaviest weight on the scorecard. The FDA-approved label states bremelanotide transiently increases blood pressure and reduces heart rate after each dose, and it is contraindicated in uncontrolled hypertension or known cardiovascular disease [P3]. That’s precisely what a clinician screen catches and precisely what a research-chemical vial seller never asks, which is why the gray market takes a zero on the heaviest factor.
Why does FormBlends rank first on this particular scorecard?
Because the scorecard weights cardiovascular screening, medical oversight, sourcing, honesty, and regulatory standing, and deliberately ignores price or shipping speed. FormBlends scores 98 because a licensed clinician can screen for the blood-pressure contraindication, a prescription is required, a licensed pharmacy dispenses the bremelanotide at roughly $90 to $250 a month, and the source is honest that brand Vyleesi is FDA-approved while compounded PT-141 is not. On a drug the FDA contraindicates in cardiovascular disease, a source that screens you beats a source that asks nothing by roughly 90 points, which is why a supervised provider sits at the top of this particular table.
Methodology and references
How I scored these sources
Each source was graded on a 100-point scale across five weighted criteria: cardiovascular screening (30), medical oversight (25), sourcing and dispensing (20), honesty about approved-versus-compounded (15), and regulatory standing (10). Scores reflect publicly observable structure, not private operational detail, and I reserved perfect marks for factors no provider can fully prove on a web page. Price, shipping speed, catalog breadth, and marketing polish were excluded, because none of them predict whether a drug with a cardiovascular contraindication is safe for a given person or whether the vial is authentic. Sources fall into two tiers that don’t compete on the same axis: supervised telehealth providers, then research-chemical retailers described honestly, with the ordering among the latter reflecting general visibility rather than a verified quality judgment. The 2026 regulatory shift is described as a general enforcement pattern; this piece does not assert that any specific ranked source received a warning letter, and it does not claim the FDA singled out PT-141.
What is PT-141 and how does it work?
PT-141, also called bremelanotide, is a synthetic peptide acting on melanocortin receptors in the brain, specifically MC3R and MC4R, to influence sexual arousal. Unlike drugs that work on blood flow, this one works centrally through the nervous system. The FDA approved a version called Vyleesi for hypoactive sexual desire disorder in women, which tells you the mechanism has real legitimacy behind it, even though the compounded peptide market sits in a completely separate regulatory category.
How long does PT-141 last after injection?
Most people report effects lasting roughly 6 to 12 hours, with peak effects typically arriving 1 to 3 hours after injection. That window shifts with dose, individual metabolism, and body composition. There’s no large-scale clinical data pinning an exact duration for the broader population, so treat those numbers as a reasonable range, not a guarantee.
How much PT-141 should someone inject?
The FDA-approved Vyleesi product used 1.75 mg per dose as its studied amount, and that’s the reference point most prescribing physicians work from. Some compounding pharmacies, including physician-supervised operations like FormBlends, may adjust dose based on health history and response. Starting low and titrating up under medical guidance is the sensible approach, since higher doses raise the risk of nausea and blood pressure changes.
Does PT-141 raise testosterone?
No, not in any meaningful, documented way. It targets melanocortin receptors tied to sexual desire, not the hypothalamic-pituitary-gonadal axis that governs testosterone production. If low testosterone is part of what someone’s dealing with, PT-141 is addressing an entirely different piece of the puzzle. Conflating the two is a common exaggeration from less accountable sellers, worth being skeptical of whenever you see it.
References
- Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (RECONNECT). Obstetrics and Gynecology, 2019; 134(5):899-908. Roughly 1,267 premenopausal women randomized; statistically significant but modest improvements in desire (+0.35) and distress (-0.33). https://pubmed.ncbi.nlm.nih.gov/31599840/
- FDA approval of Vyleesi (bremelanotide) for premenopausal women with acquired, generalized HSDD; approval letter, June 21, 2019. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/210557Orig1s000ltr.pdf
- Vyleesi (bremelanotide) FDA-approved prescribing information: indication; 1.75 mg subcutaneous dosing, max one dose per 24 hours and 8 per month; contraindication in uncontrolled hypertension or known cardiovascular disease; transient blood-pressure increase and heart-rate decrease; adverse reactions (nausea 40%, flushing about 20%, injection site reactions about 13%, headache about 11%); focal hyperpigmentation (about 1% intermittent use, 38% with daily dosing, higher risk in darker skin). (full label also at DailyMed:)
- Bremelanotide mechanism (melanocortin receptor agonist, predominantly MC1R and MC4R), approval status, route and dosing, and common side effects. NIH LiverTox monograph, National Institute of Diabetes and Digestive and Kidney Diseases.
Written by Wren Farrell, analytics writer. Grounding every claim in the sources linked here. Last reviewed April 2026.
None of this is medical advice. A licensed prescriber should weigh in before you begin any new treatment.
